Loading
Lung cancer medical oncologist who leads Winship Cancer Institute of Emory University and led the FLAURA trial of osimertinib.
Suresh S. Ramalingam is Executive Director of Winship Cancer Institute of Emory University, Georgia's NCI-designated comprehensive cancer centre. A thoracic medical oncologist, he was a principal investigator of the FLAURA trial establishing osimertinib as first-line therapy for EGFR-mutated non-small cell lung cancer, and has led numerous national lung cancer trials through ECOG-ACRIN.
| Title | Journal | Year |
|---|---|---|
| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | New England Journal of Medicine | 2020 |
Shares Unresectable stage III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
Shares Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags clinician-scientist, lung cancer, targeted therapy.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.
Shares Small-cell lung cancer, Non-small-cell lung cancer and the tags leadership, clinician-scientist, lung cancer.